HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.

[1]  A. Feller,et al.  HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications , 2002, International journal of cancer.

[2]  A. Feller,et al.  Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. , 2002, International journal of oncology.

[3]  L. Beckett,et al.  Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? , 2002, Cancer.

[4]  James N Ingle,et al.  HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.

[5]  K. Wester,et al.  HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma , 2002, Acta oncologica.

[6]  D. Grignon,et al.  Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Hosaka,et al.  Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  T. Tzai,et al.  Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[12]  S. Noguchi,et al.  C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. , 2000, Urology.

[13]  H. Burris.  Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). , 2000, Seminars in oncology.

[14]  D. Slamon,et al.  Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. , 1999, Seminars in oncology.

[15]  Hsiao‐Bai Yang,et al.  Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma , 1997, Virchows Archiv.

[16]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[17]  Y. Fradet,et al.  Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer , 1996 .

[18]  J. Bartlett,et al.  C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? , 1995, Cancer research.

[19]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[20]  T. Akiyama,et al.  An immunohistologic evaluation of C‐erbB‐2 gene product in patients with urinary bladder carcinoma , 1992, Cancer.

[21]  G. Prout,et al.  Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. , 1992, The Journal of urology.

[22]  M. Knowles,et al.  Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. , 1991, British Journal of Cancer.

[23]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[24]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[25]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[26]  D. Grignon,et al.  Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer , 2004, Urological Research.

[27]  D. Neal,et al.  C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. , 1996, The Journal of urology.

[28]  M. Hung,et al.  Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer , 1990, Molecular carcinogenesis.